Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.

Context.--Regulatory approval of pembrolizumab for treatment of gastric and gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring method for use of programmed death ligand-1 (PD-L1) protein expression as a companion diagnostic to identify likely responders to therapy. Obje...

Descripción completa

Detalles Bibliográficos

Publicado en:	Archives of Pathology & Laboratory Medicine Vol. 143; no. 3; pp. 330 - 338
Autores principales:	Kulangara, Karina, Zhang, Nancy, Corigliano, Ellie, Guerrero, Lindsay, Waldroup, Stephanie, Jaiswal, Dipeshkumar, Jansson, Malinka, Shah, Supriya, Hanks, Debra, Jiangdian Wang, Lunceford, Jared, Savage, Mary J., Juco, Jonathan, Emancipator, Kenneth
Formato:	equations & formulas pictorial research tables/charts Journal Article
Publicado:	College of American Pathologists Mar2019
Acceso en línea:	Ver este registro en EBSCOhost